ArticleClinical rheumatology2020
Colchicine may not be effective in COVID-19 infection; it may even be harmful?
Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Clinical course of Covid-19 in a cohort of patients with Behçet disease.Medicina clinica · 2022Article
- Clinical course of Covid-19 in a cohort of patients with Behçet disease.Medicina clinica (English ed.) · 2022Article
- [Colchicine, an old friend's perspectives for rheumatology in COVID-19: a scoping review].Revista colombiana de reumatologia · 2022Review
- Colchicine Against SARS-CoV-2 Infection: What is the Evidence?Rheumatology and therapy · 2022Review
- Antiviral effects of azithromycin: A narrative review.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.Molecular and cellular biochemistry · 2022Review
- Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?Biomedicines · 2022Review
- Drug-based therapeutic strategies for COVID-19-infected patients and their challenges.Future microbiology · 2021Review
- SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases.Biochimica et biophysica acta. Molecular basis of disease · 2021Article
- Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials.RMD open · 2021Article
- COVID-19 in patients with gout on colchicine.Rheumatology international · 2021Review
- Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review.Chinese medicine · 2021Review
- Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective.International immunopharmacology · 2021Review
- NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments.Frontiers in pharmacology · 2021Review
- The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time.Frontiers in medicine · 2021Review
- Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review.Journal of clinical medicine · 2020Review
- The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection.International journal of molecular sciences · 2020Review
- Drug repurposing and cytokine management in response to COVID-19: A review.International immunopharmacology · 2020Review
- Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19.Journal of clinical medicine · 2020Article
- Comment on "Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.